Bristol-Myers Squibb Co.

Links: Y! CELG MM R&D deep dive BMY Roulette

BMY / Message Board

Written By On Topic Only -- All Messages

Hide Replies

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

MSG #	SUBJECT	TYPE	AUTHOR	SENTIMENT	RECS	DATE POSTED
836	An Opdivo tweet	GN	Biotech2050		4	11/18/2019 1:16:03 AM

835	Re: ASH19 Top 10 picks by KOLs - Note list is specifically focused on Myeloma/Plasma Cell Dyscracia (draft in progress)	GN	JBWIN		4	11/17/2019 8:48:36 AM

834	ASH19 Top 10 picks by KOLs	GN	Biotech2050		0	11/17/2019 1:49:24 AM

833	PRO-C6 as a Heart Failure with Preserved Ejection Fraction (HFpEF) Biomarker	GN	Biotech2050		1	11/16/2019 10:33:57 AM

832	JCO 20Nov2019 Abstract "Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study"	GN	JBWIN		5	11/16/2019 8:11:46 AM

831	There will be $35B cash (as a minimum as some will also sell the $BMY shares and CVRs) which will be available for reinvestment most likely in biotech shares. .	GN	Biotech2050		1	11/16/2019 8:00:47 AM

830	Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition	GN	MineMineIt'sAllMine		10	11/15/2019 5:04:06 PM

829	BRISTOL-MYERS SQUIBB AND PFIZER ANNOUNCE RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECT OF ATRIAL FIBRILLATION SCREENING ON HEALTH OUTCOMES IN OLDER INDIVIDUALS	GN	Biotech2050		3	11/15/2019 10:41:20 AM

828	$CELG Receives CHMP Positive Opinion for REVLIMID in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma	GN	Biotech2050		7	11/15/2019 7:35:48 AM

827	Re: No press release extending bond conversion, yet...	GN	Doolen		3	11/14/2019 2:09:15 PM


	About Us • Contact Us • Follow Us on Twitter • Members Directory • Help Center • Advertise Not a member yet? What are you waiting for? Create Account Want to contribute? Support InvestorVillage by donating © 2003-2019 Investorvillage.com. All rights reserved. User Agreement